BoNT/A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy
View Patent ↗The present invention provides BoNT/A peptides as well as methods of predicting or determining immunoresistance to botulinum toxin therapy in an individual using BoNT/A peptides.
1. An isolated botulinum toxin serotype A (BoNT/A) peptide of SEQ ID NO: 1 having a length of at most 30 amino acids, said BoNT/A peptide comprising a 19 amino acid BoNT/A immunoreactive fragment consisting of amino acids 785-803 of SEQ ID NO: 1 or said 19 amino acid BoNT/A immunoreactive fragment having 1-4 conservative amino acid substitutions;
wherein said 19 amino acid BoNT/A immunoreactive fragment having 1-4 conservative amino acid substitutions is immunoreactive with BoNT/A.
2. The BoNT/A peptide of claim 1 , wherein said 19 amino acid BoNT/A immunoreactive fragment is amino acids 785-803 of SEQ ID NO: 1.
3. The BoNT/A peptide of claim 1 , wherein said BoNT/A peptide has a length of at most 25 amino acids.
4. An isolated botulinum toxin serotype A (BoNT/A) peptide of SEQ ID NO: 1 consisting of a 19 amino acid BoNT/A immunoreactive fragment consisting of amino acids 785-803 of SEQ ID NO: 1 or said 19 amino acid BoNT/A immunoreactive fragment having 1-4 conservative amino acid substitutions;
wherein said 19 amino acid BoNT/A immunoreactive fragment having 1-4 conservative amino acid substitutions is immunoreactive with BoNT/A.
5. The BoNT/A peptide of claim 4 , wherein said 19 amino acid BoNT/A immunoreactive fragment is amino acids 785-803 of SEQ ID NO: 1.
6. An isolated botulinum toxin serotype A (BoNT/A) peptide of SEQ ID NO: 1 having a length of at most 15 amino acids, said BoNT/A peptide comprising a 10 amino acid BoNT/A immunoreactive fragment consisting of amino acids 785-794 of SEQ ID NO: 1 or said 10 amino acid BoNT/A immunoreactive fragment having 1-4 conservative amino acid substitutions;
wherein said 10 amino acid BoNT/A immunoreactive fragment having 1-4 conservative amino acid substitutions is immunoreactive with BoNT/A.
7. The BoNT/A peptide of claim 6 , wherein said 10 amino acid BoNT/A immunoreactive fragment is amino acids 785-794 of SEQ ID NO: 1.
8. The BoNT/A peptide of claim 1 , wherein said BoNT/A peptide has a length of at most 20 amino acids.
9. An isolated botulinum toxin serotype A (BoNT/A) peptide consisting of a 10 amino acid BoNT/A immunoreactive fragment consisting of amino acids 785-794 of SEQ ID NO: 1 or said 10 amino acid BoNT/A immunoreactive fragment having 1-4 conservative amino acid substitutions;
wherein said 10 amino acid BoNT/A immunoreactive fragment having 1-4 conservative amino acid substitutions is immunoreactive with BoNT/A.
10. The BoNT/A peptide of claim 9 , wherein said 10 amino acid BoNT/A immunoreactive fragment is amino acids 785-794 of SEQ ID NO: 1.